Delivery Order SPE2DB22D1106-SPE2DB25FEKE4
- Not listed
- The U.S. Department of Defense's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Capecitabine 500 mg tablets (120-count units) valued at $1,628.98. This competitive delivery order, which carries a firm fixed price structure with no set-aside designation, is scheduled for completion by September 9, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,647.00 to AmerisourceBergen Drug Corp for the supply of Capecitabine 500 mg tablets (120 count) on August 14, 2025, with an ultimate completion date of August 15, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The contract was performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, the company's headquarters. As a...
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a $1,852.68 firm-fixed-price delivery order contract to Amerisourcebergen Drug Corp, a major pharmaceutical distribution company. The contract is for the supply of 4,565,070,201 Capecitabine 500 mg tablets, a prescription medication. This delivery order is part of a larger Indefinite Delivery Contract (IDC) worth up to $999,999,999.00 that Amerisourcebergen holds with the DLA, which serves as the primary vehicle for the...
- This is a firm-fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the provision of Capecitabine 150 mg tablets. The contract, valued at $1,094.60, has a period of performance through May 18, 2023. AmerisourceBergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical to deliver a...
- This federal contract award, with ID SPE2DB20D3103|SPE2DB21FQ1A4, was made by the Defense Logistics Agency (DLA) Troop Support Medical to the prime contractor Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $1,176.90 firm fixed-price delivery order is for the supply of 4554615032 - Capecitabine 500 mg Tablets, 120 tablets per bottle. The award is not designated under a set-aside program. It is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that...
- This firm fixed price delivery order was awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a global pharmaceutical sourcing and distribution company. The $1,761.90 award is for the supply of 4563170212 - CAPECITABINE 500 MG TABLET 120S, a pharmaceutical product, with a completion date of December 26, 2023. No set-aside designations were used. Amerisourcebergen Drug Corp has previously received numerous DLA contract awards...
- The Defense Logistics Agency awarded a delivery order valued at $24.4K to AmerisourceBergen Drug Corp for 30 tablets of AYVAKIT 200 mg, a targeted cancer therapy medication. The contract, awarded August 25, 2025, with completion targeted for September 16, 2025, utilizes firm fixed pricing with no set-aside designation, indicating competitive award status. Performance will occur at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Abiraterone Acetate 500 mg tablets (60-count) with a ceiling value of $8,006.80. This is a firm fixed-price delivery order with an ultimate completion date of August 5, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor that serves as a critical vendor for federal medical procurement needs across military...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for pharmaceutical supplies on August 18, 2025, with a ceiling value of $8,122.48 and an ultimate completion date of September 9, 2025. The contract involves the delivery of Ibrance 100 mg capsules (21-count packages), a brand-name oncology medication used in cancer treatment. This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitively awarded procurement. The place of...
- The Defense Logistics Agency awarded a $30,693.10 delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Cabometyx 40 mg tablets (30-count units). This competitively awarded, firm fixed-price contract, which is not set-aside for any socioeconomic program, will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of June 24, 2025. The contract represents a child delivery order issued under...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FEKE4Delivery Order
The Defense Logistics Agency awarded a $1,775.01 delivery order to AmerisourceBergen Drug Corp for Capecitabine 500 mg tablets (120-count) on April 23, 2025, with completion scheduled for April 24, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing under a delivery order arrangement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical federal medical procurement vendor serving military and veteran healthcare systems nationwide. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply an extensive range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. Capecitabine, a chemotherapy medication, falls within the diverse therapeutic portfolio covered under this contract vehicle, which supports customers including the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.8k | 4/23/25 |